ArticleJournal of virology2002
Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection.
Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 109 citations in OpenAlex.
- IL-36γ Is a Key Regulator of Neutrophil Infiltration in the Vaginal Microenvironment and Limits Neuroinvasion in Genital HSV-2 Infection.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- IL-36γ induces a transient HSV-2 resistant environment that protects against genital disease and pathogenesis.Cytokine · 2018Article
- Evasion of early antiviral responses by herpes simplex viruses.Mediators of inflammation · 2015Review
- Pan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2.PloS one · 2013Article
- Commensal bacteria modulate innate immune responses of vaginal epithelial cell multilayer cultures.PloS one · 2012Article
- Effects of particle size on toll-like receptor 9-mediated cytokine profiles.Biomaterials · 2011Article
- Loss of the type I interferon pathway increases vulnerability of mice to genital herpes simplex virus 2 infection.Journal of virology · 2011Article
- Expression of toll-like receptors in genital tract tissues from normal and HIV-infected men.American journal of reproductive immunology (New York, N.Y. : 1989) · 2011Article
- Nasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization.Clinical and vaccine immunology : CVI · 2010Article
- Development and characterization of a three-dimensional organotypic human vaginal epithelial cell model.Biology of reproduction · 2010Article
- Mucosal treatments for herpes simplex virus: insights on targeted immunoprophylaxis and therapy.Future microbiology · 2010Review
- Article
- FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection.Virology journal · 2009Article
- Salmonella enterica serovar typhimurium exploits Toll-like receptor signaling during the host-pathogen interaction.Infection and immunity · 2009Article
- A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge.Mucosal immunology · 2009Article
- FimH adhesin of type 1 fimbriae is a potent inducer of innate antimicrobial responses which requires TLR4 and type 1 interferon signalling.PLoS pathogens · 2008Article
- Broad-spectrum drugs against viral agents.International journal of molecular sciences · 2008Article
- A CpG oligodeoxynucleotide inducing anti-coxsackie B3 virus activity in human peripheral blood mononuclear cells.FEMS immunology and medical microbiology · 2007Article
- Antiinfective applications of toll-like receptor 9 agonists.Proceedings of the American Thoracic Society · 2007Review
- Quantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection.Journal of virology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Synthetic oligonucleotides containing CpG motifs in specific sequence contexts have been shown to induce potent immune responses. We have evaluated mucosal administration of two immunostimulatory sequence (ISS)-containing phosphorothioate-stabilized oligonucleotides for antiherpetic efficacy in animal models. The ISS oligonucleotides, suspended in phosphate-buffered saline, were tested in mouse and guinea pig vaginal models of herpes simplex virus type 2 (HSV-2) infection. For comparison, groups of untreated, non-ISS oligonucleotide-treated, and acyclovir-treated animals also were monitored. The results indicated that vaginal epithelial application of ISS (up to 6 h after viral inoculation) with mice lethally challenged with HSV-2 delayed disease onset and reduced the number of animals that developed signs of disease (P = 0.003). ISS application significantly increased survival rates over those of controls (P = 0.0014). The ISS also impacted an established infection in the guinea pig model of HSV-2 disease. A single administration of ISS (21 days after viral inoculation) significantly reduced the frequency and severity of HSV-2 lesions compared to results with non-ISS oligonucleotide-treated and untreated guinea pigs (P < 0.01). HSV-2 is shed from the vaginal cavity of the guinea pig in the absence of lesions, similar to the case with humans. As an additional indication of ISS efficacy, the magnitude of viral shedding also was significantly reduced in ISS-treated animals (P < 0.001). These effects appeared to be immunologically mediated, since ISS had no direct effect on HSV-2 replication in vitro using standard plaque assays. These data suggest that ISS may be useful in the treatment and control of genital herpes in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.